Ignite Creation Date:
2025-12-26 @ 10:20 PM
Ignite Modification Date:
2026-06-16 @ 5:05 PM
Study NCT ID:
NCT04261712
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-22
First Post:
2020-02-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Romania', 'Slovakia']}, 'conditionBrowseModule': {'meshes': [{'id': 'D000172', 'term': 'Acromegaly'}], 'ancestors': [{'id': 'D001849', 'term': 'Bone Diseases, Endocrine'}, {'id': 'D001847', 'term': 'Bone Diseases'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D006964', 'term': 'Hyperpituitarism'}, {'id': 'D010900', 'term': 'Pituitary Diseases'}, {'id': 'D007027', 'term': 'Hypothalamic Diseases'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 43}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2020-01-29', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2028-03', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-19', 'studyFirstSubmitDate': '2020-02-06', 'studyFirstSubmitQcDate': '2020-02-06', 'lastUpdatePostDateStruct': {'date': '2025-12-22', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2020-02-10', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2028-03', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence of treatment-emergent adverse events (TEAEs) throughout the study', 'timeFrame': 'Week 316'}], 'secondaryOutcomes': [{'measure': 'Change in insulin-like growth factor-1 (IGF-1) level', 'timeFrame': 'Week 16, Week 312'}, {'measure': 'Change in growth hormone (GH) level', 'timeFrame': 'Week 16, Week 312'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Acromegaly', 'ACROBAT', 'ADVANCE', 'Paltusotine'], 'conditions': ['Acromegaly']}, 'descriptionModule': {'briefSummary': 'A phase 2, open label, long-term extension study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Completed one of the parent studies (Acrobat Evolve \\[CRN00808-02\\] or Acrobat Edge \\[CRN00808-03\\])\n2. Females must be non-pregnant and non-lactating, and either surgically sterile, post-menopausal, or using effective method(s) of birth control\n3. Willing to provide signed informed consent\n\nExclusion Criteria:\n\n1. Clinically significant concomitant disease including, but not limited to, cardiovascular disease; moderate or severe renal insufficiency; or significant liver disease (including cirrhosis)\n2. Pituitary radiation since completing participation in parent studies\n3. History or presence of malignancy except adequately treated basal cell and squamous cell carcinomas of the skin within the past 5 years\n4. Positive test at Screening for HIV, hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCV-Ab).\n5. History of alcohol or substance abuse in the past 12 months\n6. Use of any investigational drug (other than paltusotine) within the past 30 days or 5 half-lives, whichever is longer before Screening\n7. Any condition that in the opinion of the investigator would jeopardize the subject's appropriate participation in this study.\n8. Cardiovascular conditions or medications associated with prolonged QT or those which predispose subjects to heart rhythm abnormalities\n9. Subjects with symptomatic cholelithiasis\n10. Subjects with clinically significant abnormal findings during the Screening Period, and any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardize the subject's safety or ability to complete the study"}, 'identificationModule': {'nctId': 'NCT04261712', 'briefTitle': 'A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Crinetics Pharmaceuticals Inc.'}, 'officialTitle': 'An Open Label, Long-term Extension Study to Evaluate the Safety and Efficacy of CRN00808 in Subjects With Acromegaly (ACROBAT Advance)', 'orgStudyIdInfo': {'id': 'CRN00808-05'}, 'secondaryIdInfos': [{'id': 'U1111-1245-5276', 'type': 'OTHER', 'domain': 'WHO'}, {'id': '2019-002193-31', 'type': 'EUDRACT_NUMBER'}, {'id': '2024-511921-75-00', 'type': 'CTIS'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Paltusotine', 'interventionNames': ['Drug: Paltusotine']}], 'interventions': [{'name': 'Paltusotine', 'type': 'DRUG', 'otherNames': ['CRN00808'], 'description': 'Paltusotine, once daily by mouth', 'armGroupLabels': ['Paltusotine']}]}, 'contactsLocationsModule': {'locations': [{'zip': '90095', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'Crinetics Study Site', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '60611', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Crinetics Study Site', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '02114', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Crinetics Study Site', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '43210', 'city': 'Columbus', 'state': 'Ohio', 'country': 'United States', 'facility': 'Crinetics Study Site', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '15212', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Crinetics Study Site', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '15213', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Crinetics Study Site', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '75231', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Crinetics Study Site', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '80030-110', 'city': 'Curitiba', 'state': 'Paraná', 'country': 'Brazil', 'facility': 'Crinetics Study Site', 'geoPoint': {'lat': -25.42778, 'lon': -49.27306}}, {'zip': '20231', 'city': 'Rio de Janeiro', 'country': 'Brazil', 'facility': 'Crinetics Study Site', 'geoPoint': {'lat': -22.90642, 'lon': -43.18223}}, {'zip': '21941', 'city': 'Rio de Janeiro', 'country': 'Brazil', 'facility': 'Crinetics Study Site', 'geoPoint': {'lat': -22.90642, 'lon': -43.18223}}, {'zip': '01228', 'city': 'São Paulo', 'country': 'Brazil', 'facility': 'Crinetics Study Site', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': '10676', 'city': 'Athens', 'country': 'Greece', 'facility': 'Crinetics Study Site', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'zip': '11527', 'city': 'Athens', 'country': 'Greece', 'facility': 'Crinetics Study Site 1', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'zip': '11527', 'city': 'Athens', 'country': 'Greece', 'facility': 'Crinetics Study Site 2', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'zip': '54642', 'city': 'Thessaloniki', 'country': 'Greece', 'facility': 'Crinetics Study Site', 'geoPoint': {'lat': 40.64072, 'lon': 22.93493}}, {'zip': '1062', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'Crinetics Study Site', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '1083', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'Crinetics Study Site', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '7624', 'city': 'Pécs', 'country': 'Hungary', 'facility': 'Crinetics Study Site', 'geoPoint': {'lat': 46.07617, 'lon': 18.22814}}, {'zip': '11000', 'city': 'Belgrade', 'country': 'Serbia', 'facility': 'Crinetics Study Site', 'geoPoint': {'lat': 44.80401, 'lon': 20.46513}}, {'city': 'Coventry', 'country': 'United Kingdom', 'facility': 'Crinetics Study Site', 'geoPoint': {'lat': 52.40656, 'lon': -1.51217}}, {'zip': 'LS97TF', 'city': 'Leeds', 'country': 'United Kingdom', 'facility': 'Crinetics Study Site', 'geoPoint': {'lat': 53.79648, 'lon': -1.54785}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Crinetics Pharmaceuticals Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}